A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)

Olander K.W., Sato M.A., Abrams M.A., Jerkins G.W., Lu F., Dinh P., Odani-Kawabata N., Chabi A., Shams N.K.

2021
Journal of glaucoma

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

University Eye Specialists, TN, Maryville, United States; East West Eye Institute, Los Angeles, CA; Abrams Eye Center, Cleveland, OH; Advancing Vision Research, TN, Nashville, United States; Santen Inc., Emeryville, CA; Santen Pharmaceutical Co., Ltd.Osaka, Japan

Related Publications

Felodipine re-positioned as a neuroprotectant via improved optic nerve head blood circulation in retinal ischemic rabbits and ocular hypertensive rats

Taniguchi T, Akaishi T, Hata T, Yamashita R, Esaki Y, Morofuji R, Okabe K, Fuwa M, Yamamoto Y, Guo L, Choi S, Luong V, Ota T, Sharif NA, Cordeiro MF, Kageyama M.

A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Konstas A.G.; Garhöfer G.; Lübke Y.; Voykov B.; Ropo A.

Valproic Acid Application to Modify Post Surgical Fibrosis in a Model of Minimally Invasive Bleb Surgery

Lo P.F.; Gunawan M.; Yap Z.L.; Leong C.; Kwek F.; Varadarajan J.; Wang X.; Kageyama M.; Wong T.T.

View all Glaucoma publications